Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas

Current Diabetes Reports

Volumn 12, Issue 6, 2012, Pages 705-710

  Jackson, Melanie A ^a,b   Caputo, Nicholas ^a,b   Castle, Jessica R ^a,b   David, Larry L ^a,b   Roberts, Charles T ^a,b   Ward, W Kenneth ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Legacy Health   (United States)

Author keywords

Amyloid; Assay; Bi hormonal closed loop pancreas; Cytotoxicity; Diabetes; Glucagon; Rescue treatment

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON; GLUCAGON RECEPTOR;

ANTIDIABETIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DEAMINATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; LIVER CELL; NONHUMAN; PH; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, TYPE 1; GLUCAGON; HUMANS; HYPOGLYCEMIA; INJECTIONS, SUBCUTANEOUS; INSULIN INFUSION SYSTEMS; MODELS, BIOLOGICAL; PANCREAS, ARTIFICIAL; REPRODUCIBILITY OF RESULTS; SWINE;

EID: 84870703307     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0320-5     Document Type: Article

References (33)

1. Kimball CP, Murlin Jr. Aqueous extracts of pancreas: some precipitation reactions of insulin. J Biol Chem. 1923;66:337.
2. Staub A, Behrens OK. The glucagon content of crystalline insulin preparations. J Clin Invest. 1954;33:1629-33.
3. Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010;4:1357-67. An excellent review of the nature of spontaneous glucagon aggregation into amyloid fibrils.
4. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. JMol Biol. 2006;355:501-23.
5. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21:1274-83.
6. Teoh CL, Griffin MD, Howlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell. 2011;2:116-27.
7. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science. 2009;325:328-32. Very interesting article demonstrating that packing of hormones into amyloid is the natural way that hormones are stored in secretory granules prior to their secretion.
8. El-Khatib FH, Jiang J, Damiano ER. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine. J Diabetes Sci Technol. 2009;3:789-803.
9. Ward W, Engle J, Duman H, Bergstrom C, Kim S, Federiuk I. The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors J. 2008;8:88-96.
10. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27.
11. Castle JR, Engle JM. El Youssef J, Massoud RG, Yuen KC, Kagan R, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33:1282-7.
12. Ward WK, Massoud RG, Szybala CJ, Engle JM, El Youssef J, Carroll JM, et al. In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol. 2010;4:1311-21. An article that demonstrates the near absence of glucagon fibrillation at pH 10.
13. Jackson M, Stonex T, Caputo N, El Youssef J, Branigan D, Castle JR, et al. Development of a stable formulation of liquid glucagon for use in a bihormonal pump. Presented at 2012 Scientific Session, American Diabetes Association, Philadelphia, PA; 2012.
14. Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A. 2001;98:944-9.
15. Joshi AB, Sawai M, Kearney WR, Kirsch LE. Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J Pharm Sci. 2005;94:1912-27.
16. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544-75.
17. Steiner SS, Li M, Hauser R, Pohl R. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol. 2010;4:1332-7.
18. Steiner SS, Hauser R, Li M, Feldstein R, Pohl, R. Stabilized glucagon solutions. US Patent Application # 12/891,240.
19. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. Optimization of the native glucagon sequence for medicinal purposes. J Diabetes Sci Technol. 2010;4:1322-31.
20. DiMarchi MA, Smiley DL, DiMarchi M, Chabenne JR, Day J. Glucagon analogs exhibiting enhanced solubility and stability. US Patent Application # 12/999,284.
21. Prestrelski S, Fang WJ, Carpenter JF, Kinzell J. Glucagon formulations for the treatment of hypoglycemia. US Patent Application # 13/186,275.
22. Jezek J. Stable aqueous systems comprising proteins. US Patent Application 11/994,408.
23. Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Ann Pharmacother. 2004;38:544-9.
24. Ward WK, Castle JR, Branigan D, Massoud RG. El Youssef J. Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 vs pH 10. Clin Drug Investig. 2012;32:433-8.
25. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8:179-88.
26. Almholt K, Tullin S, Skyggebjerg O, Scudder K, Thastrup O, Terry R. Changes in intracellular cAMP reported by a Redistribution assay using a cAMP-dependent protein kinase-green fluorescent protein chimera. Cell Signal. 2004;16:907-20.
27. Jiang Y, Cypess AM, Muse ED, Wu CR, Unson CG, Merrifield RB, et al. Glucagon receptor activates extracellular signalregulated protein kinase 1/2 via cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 2001;98:10102-7.
28. Pilar Lopez M, Gomez-Lechon MJ, Castell JV. Role of glucose, insulin, and glucagon in glycogen mobilization in human hepatocytes. Diabetes. 1991;40:263-8.
29. Gomez-Lechon MJ, Ponsoda X, Castell JV. A microassay for measuring glycogen in 96-well-cultured cells. Anal Biochem. 1996;236:296-301.
30. Cypess AM, Unson CG, Wu CR, Sakmar TP. Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium. J Biol Chem. 1999;274:19455-64.
31. CascieriMA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem. 1999;274:8694-7.
32. Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE, et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes. 2000; 49:2079-86.
33. Ikegami T, Cypess AM, Bouscarel B. Modulation of glucagon receptor expression and response in transfected human embryonic kidney cells. Am J Physiol Cell Physiol. 2001;281:C1396-402.